Open-Label Pharmacokinetic Study of Final Formulations of ATX-101
NCT01632917
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
ATX-101 - U.S.
DRUG:
ATX-101 - EU
Sponsor
Kythera Biopharmaceuticals